Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17009781 | 1.00 | IDH1 (0.40) | IDH1ALDH1A1HTTMAPTMAPK1 | |
| SCHEMBL17009784 | 1.00 | IDH1 (0.40) | IDH1ALDH1A1HTTMAPTMAPK1 | |
| SCHEMBL17009788 | 1.00 | IDH1 (0.40) | IDH1ALDH1A1HTTMAPTMAPK1 | |
| SCHEMBL28644741 | 0.90 | IDH1 (0.41) | IDH1ALDH1A1HTTMAPTMAPK1 | |
| SCHEMBL28644743 | 0.90 | IDH1 (0.41) | IDH1ALDH1A1HTTMAPTMAPK1 | |
| SCHEMBL19097759 | 0.89 | IDH1 (0.39) | IDH1ALDH1A1HTTMAPTMAPK1 | |
| SCHEMBL19097762 | 0.89 | IDH1 (0.39) | IDH1ALDH1A1HTTMAPTMAPK1 | |
| SCHEMBL19097760 | 0.89 | IDH1 (0.39) | IDH1ALDH1A1HTTMAPTMAPK1 | |
| SCHEMBL19097761 | 0.89 | IDH1 (0.39) | IDH1ALDH1A1HTTMAPTMAPK1 | |
| SCHEMBL17009789 | 0.88 | PKM (0.40) | IDH1ALDH1A1MAPTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3322694-B1 | 5-HYDROXYALKYLBENZIMIDAZOLES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2020-02-19 | — | — | EP | disclosed |
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-15 | — | — | US | disclosed |
| US-10414734-B2 | 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-17 | — | — | US | disclosed |
| EP-3105209-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| US-20180201585-A1 | 5-HYDROXYALKYLBENZIMIDAZOLES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-19 | — | — | US | disclosed |
| EP-3322694-A1 | 5-HYDROXYALKYLBENZIMIDAZOLES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-23 | — | — | EP | disclosed |
| US-9957235-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-01 | — | — | US | disclosed |
| US-20170197921-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| WO-2017009325-A1 | 5-HYDROXYALKYLBENZIMIDAZOLES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-19 | — | — | WO | disclosed |
| EP-3105209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015121210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414734-B2 | 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors | HRH1, HRH2, MDN1 | IDH1 75/4885ALDH1A1 237/4885HTT 1169/4885 |
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | HRH1, HRH2, HRH3 | IDH1 173/4885ALDH1A1 741/4885HTT 1369/4885 |
| US-20180201585-A1 | 5-HYDROXYALKYLBENZIMIDAZOLES AS MIDH1 INHIBITORS | HRH1, HRH2, MDN1 | IDH1 75/4885ALDH1A1 237/4885HTT 1169/4885 |
| US-20170197921-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | HRH1, HRH2, HRH3 | IDH1 173/4885ALDH1A1 741/4885HTT 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.